Neutralizing antibody responses to SARS-CoV-2: A population based seroepidemiological analysis

This study (August–September 2021) estimated the seroprevalence of SARS-CoV-2 neutralizing antibodies in the general population of Delhi and correlated it with their anti-SARS-CoV-2 IgG levels. Samples were selected by simple random sampling method. The neutralizing capacity was estimated by perform...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharma, Pragya, Gupta, Ekta, Basu, Saurav, Agarwal, Reshu, Mishra, Suruchi, Kale, Pratibha, Mundeja, Nutan, Charan, B.S., Singh, Gautam Kumar, Singh, M.M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Indian Association of Medical Microbiologists. Published by Elsevier B.V. 2022
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9359489/
https://www.ncbi.nlm.nih.gov/pubmed/35953349
http://dx.doi.org/10.1016/j.ijmmb.2022.07.009
Descripción
Sumario:This study (August–September 2021) estimated the seroprevalence of SARS-CoV-2 neutralizing antibodies in the general population of Delhi and correlated it with their anti-SARS-CoV-2 IgG levels. Samples were selected by simple random sampling method. The neutralizing capacity was estimated by performing a surrogate virus neutralization test (sVNT) (GenScript), Piscataway, NJ, USA. A total of 2233 (87.1%, 95% C.I. 85.7, 88.3) of the 2564 SARS-CoV-2 IgG seropositive samples had detectable SARS-CoV-2 neutralizing antibodies. In samples with S/CO ​≥ ​4.00, the neutralizing antibodies ranged from 94.5% to 100%. The SARS-CoV-2 neutralizing antibody seroprevalence strongly correlated with the S/CO range of IgG SARS-CoV-2 (r ​= ​0.62, p ​= ​0.002).

Ejemplares similares